13 results about "Matrix Metalloprotease" patented technology

The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and / or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

The invention belongs to the field of biological medicine, and particularly relates to double-stranded oligonucleotide of a targeted MMP-7 gene and application of the double-stranded oligonucleotide. Specifically, provided are a double-stranded oligonucleotide agent or a salt, conjugate, composition thereof for inhibiting the expression of matrix metalloproteinase 7 (MMP-7) wherein the double-stranded oligonucleotide agent comprises one sense strand and one antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 1-85 and the difference is not greater than 3 nucleotides, and / or the sense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 86-170 and the difference is not greater than 3 nucleotides. The double-strand oligonucleotide agent for inhibiting the expression of the MMP-7 or the salt thereof disclosed by the invention can obviously inhibit the expression of the MMP-7, and can be used for preventing and / or treating MMP-7 gene mediated diseases or symptoms.

The present invention relates to B-hydroxy and amino substituted carboxylic acide, which act as matrix metalloprotease inhibitor, particularly diastereomerically pure B-hydroxy carboxylic acid, corresponding processes for the synthesis of and pharmaceutical composition containing the compounds of the present invention. Compound of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriaasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compound.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The application relates to the field of geriatric treatment, in particular to application of a matrix metalloproteinase inhibitor, MSAB or a pharmaceutically acceptable salt thereof, in preparation of a medicine for preventing or treating osteoarthritis cartilage injury. The application adopts the MSAB to inhibit expression of matrix metalloproteinase in chondrocytes, reduces destruction of joint cartilage structure, and achieves the effect of preventing or treating osteoarthritis.

The application discloses a traditional Chinese medicine composition for preventing and / or treating knee osteoarthritis and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following components in parts by weight: salt eucommia 10 parts, raw rehmannia 15 parts, astragalus 20 parts, angelica 12 parts, cyathula 12 parts, chuanxiong 9 parts, steamed lycium 12 parts, bran quince 10 parts, bran white peony root 15 parts and fried licorice 5 parts. The traditional Chinese medicine composition can not only delay the progression of knee osteoarthritis, but also reduce the pain of knee osteoarthritis. Through in-vivo and in-vitro experiments, it is verified that the OARSI score of knee osteoarthritis is reduced after the treatment of the kidney marrow Ankang drink, the expression of type II collagen and matrix metalloproteinase-13 is obviously changed, the bone volume fraction of subchondral bone is reduced, the expression of pain sensitization factors secreted by peripheral nerves is improved, and the pain threshold is improved. Therefore, the kidney marrow Ankang drink has a good application prospect in the treatment of knee osteoarthritis.

The invention discloses a chimonanthus salicifolius extract and a preparation method and application thereof, and belongs to the technical field of medicines.The preparation method comprises the steps that dry chimonanthus salicifolius leaves are subjected to reflux extraction through an ethanol water solution, an ethyl acetate part is obtained through extraction, and then separation and purification are conducted through a silica gel column, gel column chromatography, a reversed-phase C18 column and semi-preparative high performance liquid chromatography in sequence to obtain the chimonanthus salicifolius extract. The high-purity target compound 1 and the high-purity target compound 2 are obtained. Compared with the prior art, an in-vitro cell experiment shows that the compound 1 and the compound 2 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M, the secretion levels of tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-2 (MMP2) can be reduced, the compound 1 can also inhibit the secretion of interleukin-2 (IL-2), and the compound 2 and the compound 1 have no obvious cytotoxicity when the concentration is less than or equal to 6.25 [mu] M and less than or equal to 25 [mu] M; safe and effective natural medicine candidate molecules are provided for gastrointestinal inflammation diseases such as functional dyspepsia, and the good clinical transformation potential is achieved.